Milestone for Arana
Thursday, 02 October, 2008
Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.
The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.
It was then further refined using the company's EvoGene optimisation technology.
Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.
Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
